Research Article

Platelet Serotonin Levels Are Associated with Plasma Soluble Leptin Receptor Concentrations in Normoglycemic Women

Luis Rodrigo Cataldo, José Suazo, Pablo Olmos, Carolina Bravo, José E. Galgani, Malin Fex, J. Alfredo Martínez, and José L. Santos

1Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
2Lund University Diabetes Centre, Clinical Research Center, Lund University, Malmö, Sweden
3Institute for Research in Dental Sciences, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
4Department of Health Sciences, Nutrition & Dietetics, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
5Department of Nutrition, Food Sciences and Physiology, Centre for Nutrition Research, University of Navarra, Pamplona, Spain
6Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
7Navarra’s Health Research Institute (IdiSNA), Pamplona, Spain
8IMDEA-Food, Madrid, Spain

Correspondence should be addressed to José L. Santos; jsantosm@uc.cl

Received 18 December 2018; Accepted 25 March 2019; Published 2 May 2019

Academic Editor: Jonathan M. Peterson

Copyright © 2019 Luis Rodrigo Cataldo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Most peripheral serotonin (5-hydroxytryptamine (5HT)) is synthetized in the gut with platelets being its main circulating reservoir. 5HT is acting as a hormone in key organs to regulate glucose and lipid metabolism. However, the relation between platelet 5HT levels and traits related to glucose homeostasis and lipid metabolism in humans remains poorly explored. The objectives of this study were (a) to assess the association between platelet 5HT levels and plasma concentration of nonesterified fatty acids (NEFAs) and some adipokines including leptin and its soluble leptin receptor (sOb-R), (b) to assess the association between platelet 5HT levels and anthropometric traits and indexes of insulin secretion/sensitivity derived from oral glucose tolerance test (OGTT), and (c) to evaluate changes in platelet 5HT levels in response to OGTT. In a cross-sectional study, 59 normoglycemic women underwent a standard 2-hour OGTT. Plasma leptin, sOb-R, total and high molecular weight adiponectin, TNFα, and MCP1 were determined by immunoassays. Platelet 5HT levels and NEFAs were measured before and after OGTT. The free leptin index was calculated from leptin and sOb-R measurements. Insulin sensitivity indexes derived from OGTT (HOMA-S and Matsuda ISICOMP) and plasma NEFAs (Adipose-IR, Revised QUICKI) were also calculated. Our data show that among metabolic traits, platelet 5HT levels were associated with plasma sOb-R (r = 0.39, p = 0.003, corrected p = 0.018). Platelet 5HT levels were reduced in response to OGTT (779 ± 237 vs. 731 ± 217 ng/10⁹ platelets, p = 0.005). In conclusion, platelet 5HT levels are positively associated with plasma sOb-R concentrations and reduced in response to glucose intake possibly indicating a role of peripheral 5HT in leptin-mediated appetite regulation.

1. Introduction

Serotonin (5-hydroxytryptamine (5HT)) is mainly synthesized by enterochromaffin cells in the gut that release large amounts of this monoamine in response to mechanical/chemical stimuli related to feeding [1]. Such gut-derived 5HT is released to systemic circulation, being transported through the body mostly within platelets [1]. Given that 5HT is not able to cross the blood-brain barrier, peripheral and brain pools of this monoamine remain independent.

The peripheral 5HT pool is composed of a major circulating fraction stored in platelets and a minor fraction that is locally produced in different tissues. Adipocytes [2] and pancreatic β-cells [3–7] are able to synthesize, release, and sense
this monoamine. 5HT signaling is transduced by a large and complex receptor family composed of fourteen subtypes [8]. Thus, locally produced or platelet-derived 5HT may theoretically act either as a hormone or as an autocrine/paracrine factor, whose diverse metabolic effects are mediated by the specific set of 5HT receptors expressed or activated in target cells [9, 10].

Peripheral 5HT appears to influence glucose and lipid metabolism in different cell types including white and brown adipocytes, β-cells, myocytes, and hepatocytes [6, 9–13]. 5HT infusion in humans and dogs increases plasma nonesterified fatty acids (NEFAs) and glycerol concentrations [14]. Consistently, 5HT has shown to negatively regulate lipogenesis in human preadipocytes [15]. Pharmacological studies in genetically manipulated mice are consistent with these findings, demonstrating that gut-derived 5HT increases during fasting and promotes lipolysis in adipocytes and gluconeogenesis in hepatocytes. This report suggested that peripheral 5HT acts as a multifunctional molecule for fasting adaptation in mice [16].

Additional actions of peripheral 5HT in adipocytes include the regulation of production/activity of some adipokines. 5HT in murine 3T3-L1 adipocytes reduces the expression of adiponectin and increases that of PAI1 [17]. Moreover, a recent interventional study in healthy volunteers has shown that an acute tryptophan depletion, which decreased the brain 5HT content, reduced the plasma levels of the soluble leptin receptor (sOb-R) in women [18]. The actions of leptin in the Central Nervous System (CNS) include the regulation of glucose homeostasis and appetite control. It has been described that the availability of leptin in the CNS is partially modulated by circulating sOb-R. Then, a possible regulation of peripheral 5HT on production/activity of leptin or its inhibitor sOb-R may indirectly impact on glycemic traits and eating behavior. Thus, it is important to evaluate if there is any association between peripheral 5HT levels (mostly stored in platelets) and those circulating adipokines in humans, especially leptin and sOb-R.

Parallelly, several experimental approaches have demonstrated that 5HT regulates pancreatic β-cell differentiation, proliferation, and function [3, 9, 19–26]. Remarkably, during gestation, the expression of genes encoding 5HT synthesis enzymes and 5HT content itself is hugely increased in β-cells, promoting its proliferation to face the increased insulin resistance in peripheral tissues [19, 20]. Moreover, depending on the physiological context [9, 10], 5HT positively or negatively regulates glucose-stimulated insulin secretion (GSIS) in a receptor-dependent or receptor-independent manner in various β-cell models and animal or human pancreatic islets [3, 4, 20, 21, 23, 24, 27]. Emphasizing a possible important role of peripheral 5HT in glucose homeostasis, a metabolic study in humans analyzed changes in plasma metabolites after an oral glucose tolerance test (OGTT) and found that 5HT is one of the main reduced metabolites in serum after 2 h of glucose load [28], suggesting a physiological role of peripheral 5HT in insulin secretion regulation in humans.

In spite of the increasing amount of information relating circulating 5HT to glucose and lipid metabolism, the association between platelet 5HT and glucose and lipid traits has been poorly explored in humans. In the present study, we evaluated if platelet 5HT levels are associated with plasma adipokine levels, with glucose- and lipid-related metabolic traits, and with OGTT-derived insulin secretion/sensitivity indexes in healthy normoglycemic women.

### 2. Subjects and Methods

#### 2.1. Subjects.

A cross-sectional study was carried out in nondiabetic nulliparous, nonpregnant women (n = 59, age: 27 ± 6 years, BMI: 23.6 ± 3 kg/m², glycemia: 77.6 ± 5.9 mg/dL (mean ± SD)) with no history of diabetes among their parents (Table 1). Additional inclusion criteria of this group were normal levels of plasma lipids, no hypertension, and no obesity, as well as normal hematologic parameters and no alterations in plasma hepatic-related enzymes. These women were submitted to a standard oral glucose tolerance test (OGTT), and blood samples were drawn before (-15 and -5 min) and after (15, 30, 60, and 120 min) the oral glucose (75 g) load. Plasma leptin, adiponectin (total and HMW), and sOb-R levels were measured before (-15 min) OGTT. Plasma concentration of NEFAs, TNFα, and MCP1 as well as platelet 5HT levels were measured before (-15 min) OGTT. Plasma levels of glucose and insulin were measured before and during OGTT. The research protocol of this study was approved by the Institutional Review Board of the School of Medicine, Pontificia Universidad Católica de Chile.

#### 2.2. Plasma and Serum Biochemical Determinations.

Venous blood samples were obtained at the clinical research facilities of the Red Salud UC (Santiago, Chile) and collected in vacuum tubes using sodium fluoride and EDTA as anticoagulants for glucose measurement and in serum separator gel tubes for insulin measurements. Glucose and insulin levels were measured in the Central Clinical Laboratory at Red Salud UC by the standard colorimetric glucose oxidase method (expressed in mg/dL) and by electrochemiluminescence immunoassay.
Table 2: Plasma levels of NEFAs, adipokines, and platelet 5HT in the study population.

| Phenotype | Overall (mean ± SD) | n | Range |
|-----------|---------------------|---|-------|
| NEFAs (-15 min) (μEq/L) | 578.8 ± 189.1 | 55 | 116-1034 |
| NEFAs (120 min) (μEq/L) | 104.4 ± 43.5 | 55 | 43-230 |
| Leptin (ng/mL) | 17.8 ± 8.6 | 55 | 4.7-41.3 |
| sOb-R (ng/mL) | 24.3 ± 7.7 | 55 | 9.7-43.8 |
| Adiponectin (μg/mL) | 11.4 ± 4.4 | 55 | 2.9-23.3 |
| HMW adiponectin (μg/mL) | 3.47 ± 1.47 | 55 | 0.1-6.8 |
| TNFa (-15 min) (pg/mL) | 2.73 ± 1.83 | 52 | 0.48-10.5 |
| TNFa (120 min) (pg/mL) | 2.47 ± 1.65 | 52 | 0.47-9.0 |
| MCP1 (-15 min) (pg/mL) | 64.1 ± 59.4 | 54 | 15.0-432.3 |
| MCP1 (120 min) (pg/mL) | 54.1 ± 23.5 | 54 | 15.0-149.9 |
| Platelet 5HT (-15 min) (ng/10^9 platelets) | 779 ± 237 | 59 | 237-1366 |
| Platelet 5HT (120) (ng/10^9 platelets) | 731 ± 217 | 52 | 255-1181 |

(Expressed in μU/mL), respectively. Serum NEFA concentrations were determined by an enzymatic colorimetric method (NEFA-HR, Wako Chemicals, Richmond, VA). Leptin, adiponectin, and c-peptide concentrations were determined by radioimmunoassay (RIA) while sOb-R and high molecular weight (HMW) adiponectin by a commercially available ELISA (R&D Systems, codes: DOBRO0 and DHWAD0, respectively). TNFa and MCP1 levels were measured by the multiplex technology in a MAGPIX instrument (Merck) using a commercial kit (HMHEMAG-34K). The mean ± SD concentrations of all of these variables are listed in Table 2.

2.3. Measurement of Platelet 5HT Levels. Platelet 5HT was measured by means of High-Performance Liquid Chromatography (HPLC) coupled to an electrochemical detector as previously reported [29]. Briefly, platelet-rich plasma (PRP) was obtained from EDTA-blood samples by centrifuging at 200g for 10 min at room temperature. The number of platelets in PRP was counted using a hemocytometer. 5HT was extracted from PRP samples adding perchloric acid (3.4 M), leaving for 30 min in ice for total protein precipitation, and centrifuging at 33,000g for 15 min at 4°C. 5HT mass was estimated by interpolation into a calibration curve and expressed as ng of 5HT by 10^9 platelets. The HPLC systems consisted of an Ultrasphere 5 μm ODS column (Hichrom, Theale, UK), a Rheodyne manual injector (Sigma-Aldrich, St. Louis, MO), and Waters 515 HPLC pump (Waters, Milford, MA). The HPLC mobile phase was 0.1 M sodium acetate at 1 mL/min. The Waters 464 electrochemical detector was set at 500 mV, a current of 10 nA, and a latency of 5 s using the Empower software (Waters, Milford, MA).

2.4. Insulin Secretion/Sensitivity Indexes. Based on plasma glucose and serum insulin levels taken before and during the OGTT, some metabolic indexes were calculated. HOMA-S (the inverse of HOMA-IR (HOMA – S = 1/ HOMA – IR)) and the Matsuda ISICOMP were used as surrogates of insulin sensitivity indexes derived from OGTT and calculated as previously reported [30]. By using basal NEFA concentrations, other insulin sensitivity indexes were also calculated to derive Adipose-IR and Revised QUICKI [31]. As surrogate variables of insulin secretion, two indexes were used: the ratio of the total area under the insulin curve relative to the total area under the glucose curve (ratio of AUC insulin/glucose or AUCI/G-R) or relative to the total area under the c-peptide curve (ratio of AUC insulin/c-peptide or AUCR-P-C) [32–35]. Additionally, we calculated the free leptin index (FLI) as the ratio of leptin to the sOb-R concentrations, multiplied by 100 [36].

2.5. Statistical Analysis. Associations between fasting platelet 5HT levels and metabolic variables were assessed by Spearman nonparametric correlations and Wilcoxon nonpaired tests. The statistical power estimation for our sample was done considering changes in serum 5HT during OGTT reported by Ho et al. [28]. A sample size of n = 59 provides a statistical power of >90% with a confidence of 95% to detect significant changes. Statistical significance was set at p < 0.05. STATA 12.0 software (http://www.stata.com) and GraphPad Prism 6 software (https://www.graphpad.com) were used for statistical analysis. The Bonferroni method was applied for multiple comparison correction.

3. Results

3.1. Platelet 5HT Levels and Adipokine-Related Variables. In fasted conditions, platelet 5HT levels were directly correlated with plasma sOb-R (rho = 0.39, p = 0.003) (Figure 1(a)) and TNFa concentrations (rho = 0.30, p = 0.03) (Figure 1(b)). Platelet 5HT levels were also negatively correlated with FLI (rho = −0.34, p = 0.011) (Figure 1(c)). In turn, we found a positive correlation between TNFa and sOb-R (rho = 0.31, p = 0.015). Platelet 5HT levels were not associated with other adipokines such as MCP1 and leptin, as well as total or HMW adiponectin (data not shown). Only statistical association between platelet 5HT and plasma sOb-R remained significant after Bonferroni correction of multiple comparisons derived from other adipokines tested in this study (6 tests; corrected p = 0.018). Additionally, we found a borderline association between platelet 5HT levels and plasma NEFA concentrations (rho = −0.25, p = 0.069) (Figure 1(d)).

3.2. Platelet 5HT Levels and Insulin Sensitivity/Secretion Indexes. We then evaluated whether the fasted platelet 5HT levels were associated with indexes of insulin sensitivity or secretion derived from OGTT in normoglycemic women. We did not find any significant association between the platelet 5HT levels and indexes of insulin sensitivity (Matsuda ISICOMP) (Figure 2(a)). Analysis considering additional insulin sensitivity indexes (HOMA-S, Adipose-IR, and Revised QUICKI) (data not shown) did not show any significant association. We also found no association between platelet 5HT levels and BMI and surrogate indexes of insulin secretion (AUC-IGR and AUCR-P-C) (Figures 2(b) and 2(c)).
3.3. Platelet 5HT Levels in response to OGTT. We evaluated whether platelet 5HT levels changed in response to oral glucose challenge in normoglycemic women. We found a slight but significant decrease in platelet 5HT content adjusted by the platelet number (779 ± 237 vs. 731 ± 217 ng/10⁹ platelets, -15 vs. 120 min, p < 0.005) (Figure 3(a)). Additionally, the platelet number was also reduced in response to OGTT (249 ± 59 vs. 238 ± 57 platelets ×1000/mm³, p < 0.0001).

Given the positive correlation between platelet 5HT levels and plasma TNFα concentration, we also evaluated levels of this adipokine before and after OGTT. We found a slight but significant reduction of plasma TNFα concentration in response to glucose loads in our study group (273 ± 186 vs. 2.47 ± 1.65 pg/mL, -15 vs. 120 min, p = 0.0001) (Figure 3(b)).

4. Discussion

There is accumulating evidence indicating that peripheral 5HT plays a physiological role regulating glucose and lipid metabolism and showing the ability 5HT has to modulate hormone secretion on β-cells and adipocytes. To gain insight into the physiological role of peripheral 5HT in humans, we have studied the relationship between platelet 5HT levels and metabolic traits.

It is important to take into account that although platelet 5HT represents most of the circulating pool of 5HT (~98%), it is perhaps less representative of the bioactive pool than the free circulating 5HT. Nonetheless, there is no reliable protocol to measure the free circulating 5HT (known as platelet-poor plasma (PPP) 5HT) [37]. Technical artefacts associated with the sample collection and processing, for example, the anticoagulant and antiaggregant agents used as well as the temperature and sheer forces, could dramatically affect the PPP 5HT values (due to platelet activation and releases of high amount of 5HT), and, thus, it is highly not recommended to make conclusions from PPP data [37, 38]. Those technical difficulties have been reflected in a wide range of PPP 5HT reference values reported for humans [37, 39]. Likewise, random changes in PPP 5HT levels, also observed after OGTT in humans, lead to a reasonable doubt in the utility of those measurements [40]. Considering that, we have measured the platelet 5HT instead of PPP 5HT levels in this study.
Leptin and adiponectin are important adipokines regulating energy balance that communicates white adipose tissue with other metabolically relevant tissues such as those of the skeletal muscle, endocrine pancreas, and brain [41, 42]. Imbalances in plasma levels of those hormones are associated with obesity and diabetes [43–45]. In addition, the ratio of leptin/adiponectin (either total or HMW adiponectin) constitutes a useful biomarker of systemic insulin sensitivity [30, 46]. Thus, we first evaluated whether platelet 5HT levels were associated with plasma leptin and adiponectin concentration in normoglycemic women. We did not find significant association between platelet 5HT levels and these adipokines. Our results contrast with a study showing a positive correlation between urine 5HT concentration (as a
surrogate of peripheral 5HT) and serum adiponectin concentrations in overweight individuals [47]. The fact that our study was only based on women could not explain the discrepant results, because, in fact, the former study found statistical significance for the mentioned variables in women but not in men [47]. Nonetheless, in contrast to our report, the study population of that investigation was mostly overweight insulin-resistant individuals. Other study has found a reduction in the plasma adiponectin and 5HT levels in dogs subjected to an ad libitum feeding-induced obesity protocol for six months [48]. Thus, it is possible that changes explaining the association between these two hormones are caused by imbalance under overweight/obesity conditions that we were unable to detect in our normoweight study group.

The lack of association between platelet 5HT and plasma adiponectin and leptin levels we found in this study contrasts with a study showing an upregulation of a 5HT receptor signaling cascade in hypertrophic 3T3-L1 adipocytes associated with decreased adiponectin expression [17] as well as with a report showing that 5HT decreases leptin mRNA levels and protein release from rat adipocytes and that subcutaneous injections of 5HT reduced their plasma leptin levels [2]. However, from our study, we cannot exclude a regulatory role of the locally present 5HT in leptin and adiponectin production/release from adipocytes. Although we were unable to determine an association between platelet 5HT levels and plasma leptin and adiponectin concentration, we found a positive correlation between platelet 5HT levels and plasma sOb-R concentrations in normoglycemic women. Our finding may reflect a direct positive regulation of 5HT on sOb-R production or release. In line with our finding, a recent interventional study shows that healthy female volunteers following a protocol to suppress 5HT production (feeding a tryptophan-free diet) have reduced plasma sOb-R concentrations [18]. The sOb-R constitutes the soluble fraction of leptin receptors that regulates the circulating concentration of free leptin and consequently inhibits its actions [49–52]. This is also consistent with the negative correlation we have found between platelet 5HT levels and FLI. Thus, the positive relation between platelet 5HT and plasma sOb-R concentrations found here agrees with previous studies showing that 5HT reduces leptin activity.

The serotonergic and leptin pathways are intrinsically associated within the CNS in the regulation of food intake, energy homeostasis, and glucose and fat metabolism [53, 54]. Due to both leptin and 5HT which can be released by adipocytes [2], it is possible that 5HT interacts not only with leptin pathways in the brain but also with leptin production or release on adipocytes or, even, regulates its bioavailability or bioactivity. In this case, peripheral 5HT may also act as an indirect negative regulator of leptin signaling in the brain. Our findings of the positive correlation between platelet 5HT and plasma sOb-R concentrations and the negative correlation between platelet 5HT levels and FLI seem to agree with this hypothesis, and future studies will need to further investigate this possible interaction between peripheral and central regulation between 5HT and leptin actions.

We then evaluated whether the platelet 5HT levels were associated with plasma concentrations of TNFa and MCP1. We found that platelet 5HT levels were positively correlated with plasma TNFa concentrations, a proinflammatory adipokine present in higher levels in obese individuals and subjects with insulin resistance [54]. Using Tph1 (-/-) mice (lacking peripheral 5HT), Duerschmied et al. have shown that 5HT directly stimulates the activity of the TNFa-convertong enzyme (TACE/ADAM17) [55]. TACE is a sheddase which increases the release of TNFa from its inactive cell-bound precursor [54]. This data support the idea that 5HT would be acting as a positive regulator of TNFa release.

Similar to TNFa levels, the plasma sOb-R levels appear to be increased during inflammatory episodes in humans and animals [56–58]. In addition, treating mice with proinflammatory agents leads to elevated plasma sOb-R concentrations [58]. In line with the reported higher plasma levels of these two proteins in different pathophysiological states, we found a nominal positive correlation between plasma TNFa and sOb-R concentrations in normoglycemic women. These positive associations may reflect a common mechanism of regulation of sOb-R and TNFa production/release or, alternately, a direct regulation between each other. In support of that hypothetical interaction, in vitro analysis has shown that TNFa upregulates sOb-R release via ectodomain shedding of long-isofrom leptin receptor in several cell types [59]. Thus, considering our data altogether, it is possible to hypothesize a more complex regulatory mechanism in which peripheral 5HT may indirectly enhance sOb-R through the positive regulation of TNFa.

In this study, we have also found a reduction of both platelet 5HT content and total platelet count in response to OGTT. In accordance with our result, a study analyzing more than 110 metabolites from 377 nondiabetic individuals in response to OGTT found that plasma 5HT was markedly decreased after glucose load [28]. The magnitude of the change of the circulating 5HT reported in the former study (>2-fold) was much higher than the one reported here. This difference may be due to experimental discrepancies between the former and our study: the characteristic of the study group (insulin resistant vs. healthy women) and the fraction (free vs. platelet 5HT) and method of circulating 5HT quantified (mass spectrometry vs. HPLC) [28]. In contrast with our results, other authors measuring various plasma neurotransmitters in response to OGTT in 100 healthy individuals have found significant increases in platelet 5HT levels [40]. Differences in the group composition (56 vs. 0% males), plasma sample processing, and data calculation may explain our opposed findings; in fact, they have not normalized the 5HT content by the platelet number as it must be. Moreover, these authors have found an increase in platelet 5HT and plasma noradrenalin levels in the individuals that were subjects to a sham-feeding test where they drank a sweetened solution without glucose, meaning the increases of neurotransmitter they observed in response to OGTT may not reflect an effect of the oral glucose load. Other special features of 5HT metabolism could also explain the opposed results, for example, the inter- or intraindividual differences in gut 5HT production or the uptake rate in platelets or in peripheral tissues via SERT (5HT transporter) [60], which could be, in turn, inhibited by the antidepressant drugs (serotonin selective reuptake
inhibitor (SSRI)) [61]. The intake of 5HT-rich foods such as nuts, pineapples, and bananas may also contribute to such interindividual differences in platelet 5HT content [62]. In our study, these interferers were considered exclusion criteria and advertised to participants.

As previously mentioned, there are evidences showing that 5HT acting on β-cells inhibits GSIS [3, 7, 21, 22, 24–26, 63–65]. In this study, we have found a reduction of circulating 5HT level in response to glucose load. Thus, a reduction of the inhibitory effect of 5HT signaling in β-cells might be necessary for the physiological GSIS, and it would be in line with evidences showing a deregulated 5HT signaling in β-cells of subjects with type 2 diabetes (T2D) [3, 66, 67]. However, from our data, we cannot discard the possibility that the observed reduction of platelet 5HT levels in response to OGTT would be a simple consequence of an increased platelet activation in response to the physiological mechanism induced by glucose uptake.

An additional aim of the current study was to assess whether the platelet 5HT levels were associated with OGTT-derived indexes of insulin sensitivity (Matsuda) or secretion (AUC-IGR and AUCR-P-C). We found no association between platelet 5HT levels and any of these OGTT-derived indexes. These results may reflect that in a physiological range of platelet 5HT levels, such as those found in a cohort of normoglycemic women, the control of peripheral 5HT on insulin sensitivity and secretion may be masked by the multiple metabolic processes potentially regulated by this monoamine. In this context, it has been shown that peripheral 5HT also promotes gluconeogenesis in hepatocytes and negatively regulates energy expenditure by inhibiting the noradrenaline-mediated thermogenesis on brown adipocytes in mice [12, 13]. Therefore, it is probably that imbalance on 5HT local production or free circulating 5HT levels during pathophysiological states, possibly not detected by measuring the platelet 5HT, may contribute to the metabolic disorder progression. In agreement, higher free circulating 5HT but lower platelet 5HT levels has been reported in T2D patients, which has been proposed to be consequences of an increased platelet activation and degranulation under the metabolically adverse low-grade inflammatory states [68–70]. Furthermore, higher plasma and urinary levels of 5-hydroxyindole-3-acetic acid (5-HIAA), a 5HT metabolite, has been associated with metabolic syndrome and diabetes [70, 71].

Thus, the lack of associations between the platelet 5HT and metabolic traits found in this study may be explained by the relatively homogeneous, normoglycemic, mainly normoweight women (with no family history of diabetes) selected for this survey or maybe by the fact that we were measuring the massive amount of platelet 5HT content which is, as previously mentioned, less representative of the bioactive pool than the free 5HT. Additionally, the relatively small sample size (n = 59), the lack of information about other risk factors influencing insulin sensitivity such as diet or physical exercise, and the simple observational nature of this study may be considered weaknesses of our research design that may contribute to the decrease in the statistical power of this study.

Therefore, future studies should measure free circulating 5HT (by means of its metabolite 5HIAA) in a large cohort of healthy, glucose-intolerant, and T2D individuals to evaluate whether in a pathophysiological state peripheral 5HT levels explain the differences in insulin sensitivity and/or insulin secretion. Additionally, interventional studies to modify the peripheral 5HT levels, for example, using tryptophan-restricted diet or SSRI drugs, must be performed in humans in order to unveil whether peripheral 5HT is causally associated with alterations of insulin sensitivity or secretion or with appetite regulation.

5. Conclusions

We found that platelet 5HT levels are slightly reduced in response to glucose intake and that platelet 5HT levels are positively associated with plasma sOb-R concentrations in normoglycemic women. These findings might reflect a potential role of peripheral 5HT in leptin-mediated appetite regulation.

Our data also indicates that platelet 5HT levels are not associated with indexes of insulin secretion/sensitivity and glycemic-related traits or BMI in this group of Chilean normoglycemic women. Therefore, it is likely that changes in free circulating 5HT or in locally produced key tissues rather than those in platelet 5HT levels explain the reported actions for peripheral 5HT regulating glucose and lipid metabolism.

Data Availability

All the data used in this study are available upon request to the corresponding author.

Conflicts of Interest

All the authors declare that there is no conflict of interest associated with this manuscript.

Acknowledgments

The authors wish to thank all individuals who voluntarily cooperated to carry out this study. This research was funded by grants FONDECYT 1120586 (JLS) and FONDECYT 1150416 (JLS); Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain (CB12/03/30002) (JAM); and Postdoctoral fellowship CONICYT grant 74180010 (LRC).

References

[1] G. M. Mawe and J. M. Hoffman, "Serotonin signalling in the gut–functions, dysfunctions and therapeutic targets," Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 8, pp. 473–486, 2013.

[2] A. K. Stunes, J. E. Reseland, Ø. Hauso et al., "Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation," Diabetes, Obesity and Metabolism, vol. 13, no. 6, pp. 551–558, 2011.

[3] H. Bennet, A. Balhuizen, A. Medina et al., "Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to
defective insulin and glucagon secretion in human type 2 diabetes,” Peptides, vol. 71, pp. 113–120, 2015.

[4] L. R. Cataldo, M. L. Mizgier, D. Busso et al., “Serotonin- and dopamine-related gene expression in db/db mice islets and in MIN6 β-cells treated with palmitate and oleate,” Journal of Diabetes Research, vol. 2016, Article ID 3793781, 12 pages, 2016.

[5] Y. Ohta, Y. Kosaka, N. Kishimoto et al., “Convergence of the insulin and serotonin programs in the pancreatic β-cell,” Diabetes, vol. 60, no. 12, pp. 3208–3216, 2011.

[6] L. R. Cataldo, V. A. Cortés, J. E. Galgani, P. R. Olmos, and J. L. Santos, “Role of peripheral serotonin in the insulin secretion and glucose homeostasis,” Nutricion Hospitalaria, vol. 30, no. 3, pp. 498–508, 2014.

[7] L. R. Cataldo, V. Cortés, M. Mizgier et al., “Fluoxetine impairs insulin secretion without modifying extracellular serotonin levels in MIN6 β-cells,” Experimental and Clinical Endocrinology & Diabetes, vol. 123, no. 8, pp. 473–478, 2015.

[8] D. E. Nichols and C. D. Nichols, “Serotonin receptors,” Chemical Reviews, vol. 108, no. 5, pp. 1614–1641, 2008.

[9] L. R. Cataldo Bascuñán, C. Lyons, H. Bennet, I. Artner, and M. Fex, “Serotonergic regulation of insulin secretion,” Acta Physiologica, vol. 225, no. 1, article e13101, 2019.

[10] R. El-Merabbi, M. Loffler, A. Mayer, and G. Sumara, “The roles of peripheral serotonin in metabolic homeostasis,” FEBS Letters, vol. 589, no. 15, pp. 1728–1734, 2015.

[11] D. D. Lam and L. K. Heisler, “Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes,” Expert Reviews in Molecular Medicine, vol. 9, no. 5, pp. 1–24, 2007.

[12] J. D. Crane, R. Palanivel, E. P. Mottillo et al., “Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis,” Nature Medicine, vol. 21, no. 2, pp. 166–172, 2015.

[13] C. M. Oh, J. Namkung, Y. Go et al., “Regulation of systemic energy homeostasis by serotonin in adipose tissues,” Nature Communications, vol. 6, no. 1, article 6794, 2015.

[14] L. A. Carlson, L. G. Ekelund, and L. Oro, “Metabolic and cardio-vascular effects of serotonin,” Life Sciences, vol. 6, no. 3, pp. 261–271, 1967.

[15] J. Söhle, N. Machuy, E. Smilbegovic et al., “Identification of new genes involved in human adipogenesis and fat storage,” PLoS One, vol. 7, no. 2, article e31193, 2012.

[16] G. Sumara, O. Sumara, J. K. Kim, and G. Karsenty, “Gut-derived serotonin is a multifunctional determinant to fasting adaptation,” Cell Metabolism, vol. 16, no. 5, pp. 588–600, 2012.

[17] S. Uchida-Kitajima, T. Yamaiuchi, Y. Takashina et al., “5-Hydroxytryptamine 2A receptor signaling cascade modulates adiponectin and plasminogen activator inhibitor 1 expression in adipose tissue,” FEBS Letters, vol. 582, no. 20, pp. 3037–3044, 2008.

[18] F. D. Zepp, V. L. S. Dingerkus, K. Helmbold et al., “Effects of a short-term reduction in brain serotonin synthesis on the availability of the soluble leptin receptor in healthy women,” Journal of Neural Transmission, vol. 122, no. 3, pp. 343–348, 2015.

[19] H. Kim, Y. Toyofuku, F. C. Lynn et al., “Serotonin regulates pancreatic beta cell mass during pregnancy,” Nature Medicine, vol. 16, no. 7, pp. 804–808, 2010.

[20] M. Obara-Imaizumi, H. Kim, M. Yoshida et al., “Serotonin regulates glucose-stimulated insulin secretion from pancreatic β cells during pregnancy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 48, pp. 19420–19425, 2013.

[21] N. Paulmann, M. Grohmann, J. P. Voigt et al., “Intracellular serotonin modulates insulin secretion from pancreatic β-cells by protein serotonylation,” PLoS Biology, vol. 7, no. 10, article e1002229, 2009.

[22] L. R. Cataldo, M. L. Mizgier, R. Bravo Sagué et al., “Prolonged activation of the Htr2b serotonin receptor impairs glucose stimulated insulin secretion and mitochondrial function in MIN6 cells,” PLoS One, vol. 12, no. 1, article e0170213, 2017.

[23] H. Benne, I. G. Mollet, A. Balhuizen et al., “Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans,” Diabetologia, vol. 59, no. 4, pp. 744–754, 2016.

[24] Q. Zhang, Y. Zhu, W. Zhou, L. Gao, L. Yuan, and X. Han, “Serotonin receptor 2C and insulin secretion,” PLoS One, vol. 8, no. 1, article e45230, 2013.

[25] E. Gylle, “Association between 5-hydroxytryptamine release and insulin secretion,” Journal of Endocrinology, vol. 78, no. 2, pp. 239–248, 1978.

[26] A. Lerman, “The significance of 5-hydroxytryptamine for insulin secretion in the mouse,” Hormone and Metabolic Research, vol. 3, no. 5, pp. 305–309, 1971.

[27] K. Kim, C. M. Oh, M. Obara-Imaizumi et al., “Functional role of serotonin in insulin secretion in a diet-induced insulin-resistant state,” Endocrinology, vol. 156, no. 2, pp. 444–452, 2015.

[28] J. E. Ho, M. G. Larson, R. S. Vasan et al., “Metabolite profiles during oral glucose challenge,” Diabetes, vol. 62, no. 8, pp. 2689–2698, 2013.

[29] A. M. Kumar, M. Kumar, K. Deepika, J. B. Fernandez, and C. Eisdorfer, “A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelet, and plasma,” Life Sciences, vol. 47, no. 19, pp. 1751–1759, 1990.

[30] C. Bravo, L. R. Cataldo, J. Galgani, J. Parada, and J. L. Santos, “Leptin/adiponectin ratios using either total or high-molecular-weight adiponectin as biomarkers of systemic insulin sensitivity in normoglycemic women,” Journal of Diabetes Research, vol. 2017, Article ID 9031079, 11 pages, 2017.

[31] L. M. Brady, B. A. Gower, S. S. Lovegrove, C. M. Williams, and J. A. Lovegrove, “Revised QUICKI provides a strong surrogate estimate of insulin sensitivity when compared with the minimal model,” International Journal of Obesity, vol. 28, no. 2, pp. 222–227, 2004.

[32] S. M. Haffner, C. Gonzalez, H. Miettinen, E. Kennedy, and M. P. Stern, “A prospective analysis of the HOMA model: The Mexico City Diabetes Study,” Diabetes Care, vol. 19, no. 10, pp. 1138–1141, 1996.

[33] S. M. Haffner, H. Miettinen, and M. P. Stern, “The homeostasis model in the San Antonio Heart Study,” Diabetes Care, vol. 20, no. 7, pp. 1087–1092, 1997.

[34] M. Stumvoll, A. Mitrokou, W. Pimenta et al., “Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity,” Diabetes Care, vol. 23, no. 3, pp. 295–301, 2000.

[35] M. Stumvoll, T. Van Haeften, A. Frische, and J. Gerich, “Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times,” Diabetes Care, vol. 24, no. 4, pp. 796–797, 2001.
[36] M. Owecki, E. Nikisch, A. Miczke, D. Pupek-Musialik, and J. Sovinski, “Free leptin index as a marker for leptin action in diabetes and obesity: leptin and soluble leptin receptors relationship with HbA1C,” Neuro Endocrinology Letters, vol. 31, no. 5, pp. 679–683, 2010.

[37] T. Brand and G. M. Anderson, “The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis,” Clinical Chemistry, vol. 57, no. 10, pp. 1376–1386, 2011.

[38] S. Yubero-Lahoz, J. Rodríguez, A. Faura et al., “Determination of free serotonin and its metabolite 5-HIAA in blood human samples with consideration to pre-analytical factors,” Biomedical Chromatography, vol. 28, no. 12, pp. 1641–1646, 2014.

[39] S. N. Young and G. N. Anderson, “Bioanalytical accuracy: a threat to the integrity and efficiency of research,” Journal of Psychiatry and Neuroscience, vol. 35, no. 1, pp. 3–6, 2010.

[40] F. Lechin, B. van der Dijks, M. Lechin et al., “Effects of an oral glucose load on plasma neurotransmitters in humans: involvement of REM sleep?,” Neuropsychobiology, vol. 26, no. 1-2, article 118889, pp. 4–11, 1992.

[41] C. H. J. Choi and P. Cohen, “Adipose crosstalk with other cell types in health and disease,” Experimental Cell Research, vol. 360, no. 1, pp. 6–11, 2017.

[42] N. Sáinz, C. J. González-Navarro, J. A. Martínez, and M. J. Moreno-Aliaga, “Leptin signaling as a therapeutic target of obesity,” Expert Opinion on Therapeutic Targets, vol. 19, no. 7, pp. 893–909, 2015.

[43] J. S. Flier, “Clinical review 94: what’s in a name? In search of leptin’s physiologic role,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 5, pp. 1407–1413, 1998.

[44] A. E. Civitarese, B. Ukwoponda, S. Carling et al., “Role of adiponectin in human skeletal muscle bioenergetics,” Cell Metabolism, vol. 4, no. 1, pp. 75–87, 2006.

[45] T. Kadowaki, T. Yamauchi, K. Harra, K. Ueki, and K. Tobe, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006.

[46] (on behalf of the European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group), F. M. Finucane, J. L. Sowinski, and R. E. Isaacson, “TNF-a up-regulates protein level and cell surface expression of the leptin receptor by stimulating its export via a PKC-dependent mechanism,” Endocrinology, vol. 153, no. 12, pp. 5821–5833, 2012.

[47] K. P. Lesch, B. L. Wolozin, D. L. Murphy, and P. Riederer, “Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter,” Journal of Neurochemistry, vol. 60, no. 6, pp. 2319–2322, 1993.

[48] Y. Bismuth-Evenzal, Y. Gionopolsky, D. Gurrwitz, I. Iancu, M. Peretz, and B. Rychen, “Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs,” Journal of Affective Disorders, vol. 136, no. 1-2, pp. 99–103, 2012.

[49] I. P. Kema, A. M. Schellings, G. Meiborg, C. J. Hoppenbrouwers, and F. A. Muskiet, “Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites,” Clinical Chemistry, vol. 38, no. 9, pp. 1730–1736, 1992.

[50] W. S. Zawalich, G. J. Tesz, and K. C. Zawalich, “Effects of prior 5-hydroxytryptamine exposure on rat islet insulin secretory and phospholipase C responses,” Endocrine, vol. 23, no. 1, pp. 11–16, 2004.

[51] I. Lundquist, R. Ekhholm, and L. E. Ericson, “Monoamines in the pancreatic islets of the mouse: 5-Hydroxytryptamine as an intracellular modifier of insulin secretion, and the hypoglycaemic action of monoamine oxidase inhibitors,” Diabetologia, vol. 7, no. 6, pp. 414–422, 1971.

[52] J. M. Feldman and H. E. Lebovitz, “Serotonin inhibition of in vitro insulin release from golden hamster pancreas,” Endocrinology, vol. 86, no. 1, pp. 66–70, 1970.

[53] S. Asad, P. Nikamo, A. Gryllenberg et al., “HTR1A a novel type 1 diabetes susceptibility gene on chromosome 5p13-q13,” PLoS One, vol. 7, no. 5, article e53439, 2012.
[67] Y. Zhang, E. M. Smith, T. M. Baye et al., “Serotonin (5-HT) receptor 5A sequence variants affect human plasma triglyceride levels,” *Physiological Genomics*, vol. 42, no. 2, pp. 168–176, 2010.

[68] M. A. Barradas, D. S. Gill, V. A. Fonseca, D. P. Mikhailidis, and P. Dandona, “Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease,” *European Journal of Clinical Investigation*, vol. 18, no. 4, pp. 399–404, 1988.

[69] K. Hara, Y. Hirowatari, Y. Shimura, and H. Takahashi, “Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease,” *Diabetes Research and Clinical Practice*, vol. 94, no. 2, pp. 167–171, 2011.

[70] M. Fukui, M. Tanaka, H. Toda et al., “High plasma 5-hydroxyindole-3-acetic acid concentrations in subjects with metabolic syndrome,” *Diabetes Care*, vol. 35, no. 1, pp. 163–167, 2012.

[71] T. Takahashi, M. Yano, J. Minami et al., “Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy,” *Diabetes Research and Clinical Practice*, vol. 58, no. 2, pp. 123–129, 2002.